FNY Investment Advisers’s Trillium Therapeutics Inc. TRIL Stock Holding History

FNY Investment Advisers’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-10,000	Closed	-$175K	–	937
2021 Q3	$175K	Buy	+10,000	New	+$117K	0.08%	166
2021 Q2	–	Sell	-39,900	Closed	-$428K	–	1056
2021 Q1	$428K	Sell	39,900 -45,100	-53%	-$558K	0.16%	116
2020 Q4	$1.25M	Buy	85,000 +65,000	+325%	+$937K	0.34%	73
2020 Q3	$284K	Sell	20,000 -197,000	-91%	-$1.96M	0.12%	137
2020 Q2	$1.75M	Buy	217,000 +132,000	+155%	+$817K	1.02%	20
2020 Q1	$343K	Buy	+85,000	New	+$321K	0.26%	80

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

FNY Investment Advisers's TRIL Position: Q4 2021 in Review

FNY Investment Advisers sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 10,000 shares — an estimated $175K sold.

FNY Investment Advisers first reported a position in TRIL in Q1 2020 and held it in 6 quarters. The position peaked at $1.75M in Q2 2020. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

FNY Investment Advisers reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
FNY Investment Advisers sold 10,000 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $175K.
FNY Investment Advisers first reported a position in Trillium Therapeutics Inc. in Q1 2020 and held it in 6 quarters.
FNY Investment Advisers's Trillium Therapeutics Inc. position peaked at $1.75M in Q2 2020.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on FNY Investment Advisers's 13F filing for Q4 2021, filed 10 Jan 2022.